Koesten, Hirschmann & Crabtree, Inc. Biogen Inc. Transaction History
Koesten, Hirschmann & Crabtree, Inc.
- $208 Million
- Q3 2025
Number of Shares
0Holding current value
$0% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BIIB
# of Institutions
1,073Shares Held
131MCall Options Held
3.82MPut Options Held
2.34M-
Vanguard Group Inc Valley Forge, PA17.3MShares$2.9 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15MShares$2.51 Billion1.66% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.44 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.32MShares$1.23 Billion0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.25MShares$712 Million0.11% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $24.1B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...